Key result
Elevated serum C1q is an independent predictor of high residual platelet reactivity in stable coronary artery disease patients receiving clopidogrel therapy.
Why the study?
Whether C1q affects ADP-induced platelet reactivity during clopidogrel therapy was unclear.
Does elevated serum C1q predict high residual platelet reactivity in stable CAD patients receiving clopidogrel therapy?
Cross-Sectional (n=1,334)
No
Does elevated serum C1q predict high residual platelet reactivity in stable CAD patients receiving clopidogrel therapy?
Elevated serum C1q levels are independently associated with high residual platelet reactivity in stable CAD patients on clopidogrel, suggesting a potential biomarker for identifying patients at risk of inadequate antiplatelet response.
Answers are grounded in this paper and cite their sources.
Should not yet change clopidogrel management in stable CAD; supports further biomarker validation in prospective studies.
Background Inflammation increases the risk of thrombosis in coronary artery disease (CAD) patients and affects the antiplatelet efficacy of clopidogrel. C1q interacts with platelets to activate platelets and induce thrombosis by participating in and regulating the inflammatory response. Whether C1q affects adenosine diphosphate (ADP)-induced platelet reactivity during clopidogrel therapy was unclear and our study aimed to explore the issue. Method We enrolled 1,334 CAD patients receiving clopidogrel therapy and evaluated the association between C1q level and high residual platelet reactivity (HRPR) using logistic regression and restricted cubic spline (RCS). HRPR was defined as ADP-induced maximum amplitude (MA ADP ) > 47 mm plus ADP-induced platelet aggregation (ADP i ) < 50%. Results A total of 516 patients (38.7%) performed HRPR. The frequency of HRPR increases with the increase in C1q level (26.3%, 38.4%, 43.2%, and 46.7% for the 1st to 4th quartile of C1q). The result of multivariate logistic regression demonstrated elevated C1q as an independent predictor for HRPR (2 nd quartile: OR = 1.722, 95% CI 1.215–2.440; 3 rd quartile: OR = 2.015, 95% CI 1.413–2.874; 4 th quartile: OR = 2.362, 95% CI 1.631–3.421, compared to the 1st quartile). RCS depicted the nonlinear relationship between C1q and HRPR risk ( p for non-linear < 0.05). Conclusion The current research is the first to explore the association of C1q and ADP-induced platelet reactivity and to demonstrate elevated C1q as an independent risk factor for HRPR in CAD patients during clopidogrel therapy.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) conducted a cross-sectional in Stable coronary artery disease (SCAD) (n=1,334). Elevated serum C1q vs. Lowest quartile of serum C1q was evaluated on High residual platelet reactivity (HRPR) (OR 2.362, 95% CI 1.631-3.421, p=<0.001). Elevated serum C1q is an independent predictor of high residual platelet reactivity in stable coronary artery disease patients receiving clopidogrel therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: